Vulvar cancer breakthrough: one test could spare women unnecessary surgery

NCT ID NCT06358469

Recruiting now Knowledge-focused Sponsor: Canadian Cancer Trials Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 4 times

Summary

This study is testing whether looking at two biological markers (HPV and p53) in early-stage vulvar cancer can help doctors decide the right amount of surgery. Some women may need less surgery, while others may need more. The study will follow 249 participants for 3 years to see how often the cancer comes back.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VULVAR SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

vulvar squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VULVAR SQUAMOUS CELL CARCINOMA

Contacts and locations

Locations

Allan Blair Cancer Centre
RECRUITING

Regina, Saskatchewan, S4T 7T1, Canada
Auckland City Hospital
RECRUITING

Auckland, 1023, New Zealand
BCCA - Kelowna
RECRUITING

Kelowna, British Columbia, V1Y 5L3, Canada
BCCA - Vancouver
RECRUITING

Vancouver, British Columbia, V5Z 4E6, Canada
BCCA - Victoria
RECRUITING

Victoria, British Columbia, V8R 6V5, Canada
CHUM-Centre Hospitalier de l'Universite de Montreal
RECRUITING

Montreal, Quebec, H2X 3E4, Canada
CIUSSS de l'Estrie - Centre hospitalier
RECRUITING

Sherbrooke, Quebec, J1H 5N4, Canada
Hotel-Dieu de Quebec
RECRUITING

Québec, Quebec, G1R 2J6, Canada
Juravinski Cancer Centre at Hamilton Health Sciences
RECRUITING

Hamilton, Ontario, L8V 5C2, Canada
Odette Cancer Centre
RECRUITING

Toronto, Ontario, M4N 3M5, Canada
The Jewish General Hospital
RECRUITING

Montreal, Quebec, H3T 1E2, Canada
University Health Network
RECRUITING

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.